NewAmsterdam Pharma Announced Dosing Of The First Patient And Initiation Of TANDEM Phase 3 Trial To Evaluate Obicetrapib And Ezetimibe FDC In Adult Patients With Heterozygous Familial Hypercholesterolemia And/Or Atherosclerotic Cardiovascular Disease
新阿姆斯特丹製藥公司宣佈爲第一位患者服藥並啓動TANDEM 3期試驗,以評估雜合子家族性高膽固醇血癥和/或動脈粥樣硬化性心血管疾病的成年患者的奧比曲匹和依澤替米貝FDC